Search results
Results from the WOW.Com Content Network
This variant was first proposed (2012) by Mayo Clinic researches. [ 4 ] though it was also reported by other groups more or less at the same time. [ 49 ] [ 50 ] It is defined as isolated demyelinating lesions which produce a progressive myelopathy similar to primary progressive MS, [ 51 ] [ 52 ] [ 53 ] and is currently considered inside the ...
Schilder disease or diffuse myelinoclastic sclerosis: is a rare disease that presents clinically as a pseudotumoural demyelinating lesion; and is more common in children. [56] [57] Solitary sclerosis: This variant was proposed (2012) by Mayo Clinic researchers. [58] though it was also reported by other groups more or less at the same time.
Tuberous sclerosis complex (TSC) is a rare multisystem autosomal dominant genetic disease that causes non-cancerous tumours to grow in the brain and on other vital organs such as the kidneys, heart, liver, eyes, lungs and skin.
Early treatment leads to a better prognosis, but a higher relapse frequency when treated with DMTs is associated with a poorer prognosis. [205] [209] A 60-year longitudinal population study conducted in Norway found that those with MS had a life expectancy seven years shorter than the general population. Median life expectancy for RRMS patients ...
Hippocampal sclerosis is the most common brain abnormality in those with temporal lobe epilepsy. [16] Hippocampal sclerosis may occur in children under 2 years of age with 1 instance seen as early as 6 months. [17] About 70% of those evaluated for temporal lobe epilepsy surgery have hippocampal sclerosis.
Historically, acute MS was a fatal disease, with death occurring within a year of onset, often secondary to extensive brainstem demyelination. Treatments include plasma exchange and/or high-dose glucocorticoids (e.g., 1 g/day of methylprednisolone for 3–5 days).
Diffuse myelinoclastic sclerosis, sometimes referred to as Schilder's disease, is a very infrequent neurodegenerative disease that presents clinically as pseudotumoural demyelinating lesions, making its diagnosis difficult.
[12] [13] [5] Without treatment, survival is typically three months. [14] It is the most common cancer that begins within the brain and the second-most common brain tumor, after meningioma, which is benign in most cases. [6] [15] About 3 in 100,000 people develop the disease per year. [3]